INmune Bio Q3 net loss $6.5M; appoints new CEO, CFO; INKmune trial meets primary endpoint

Inmune Bio, Inc.

2025-Q3 EPS reported -$1.68 revenue$50,000

Net loss narrowed to $6.5M from $12.1M YoY; R&D spend cut to $4.9M; cash $27.7M.
David Moss appointed President & CEO replacing Dr. RJ Tesi; Cory Ellspermann named CFO.
XPro1595 Phase 2 MINDFuL results manuscript submitted; End-of-Phase 2 meeting with FDA expected Q1 2026.
INKmune CARE-PC trial met primary endpoint and 2 of 3 secondary endpoints; trial closed to recruitment.
CORDStrom commercial pilot runs complete; MAA submission on track for mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.